All In Biotech

Drug Trial Radar · NCT06685692

A Clinical Trial Investigating the Safety and Efficacy of Subjects With Alcohol Associated Hepatitis (Part 1)

A Phase 2 Clinical Trial Investigating the Safety and Efficacy of ADX-629 in Subjects With Moderate Alcohol Associated Hepatitis

Last checked: Nov 19, 2026Latest source record: Jun 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

4

Actual

Start

Nov 4, 2024

Primary completion

Jun 18, 2025

Study completion Jun 18, 2025

Sponsor

Lead sponsor
Aldeyra Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Nov 12, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 2 Clinical Trial Investigating the Safety and Efficacy of ADX-629 in Subjects with Moderate Alcohol Associated Hepatitis (Part 1)

Conditions

  • Alcohol Hepatitis

Interventions

  • ADX-629Drug

    125 mg twice daily for 28 days

  • ADX-629Drug

    250 mg twice daily for 28 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment-Emergent Adverse Event QueryTime frame: Day 1 to Day 28

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Synergry Healthcare

    Bradenton, Florida

  • Florida Health Sciences Center/Tampa General Hospital/USF

    Tampa, Florida

  • The Liver Institute at Methodist Dallas Medical Center

    Dallas, Texas

  • UDL Clinical Research, LLC

    Houston, Texas

  • Methodist Specialty and Transplant Hospital

    San Antonio, Texas

  • Bon Secours Liver Institute of Newport News

    Richmond, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.